about
Metabotropic glutamate receptor 5 (mGluR5)-mediated phosphoinositide hydrolysis and NMDA-potentiating effects are blunted in the striatum of aged rats: a possible additional mechanism in striatal senescenceThe expression of native and oxidized LDL receptors in brain microvessels is specifically enhanced by astrocytes-derived soluble factor(s)Spinal cord pathology is ameliorated by P2X7 antagonism in a SOD1-mutant mouse model of amyotrophic lateral sclerosisEffects of the adenosine A2A receptor antagonist SCH 58621 on cyclooxygenase-2 expression, glial activation, and brain-derived neurotrophic factor availability in a rat model of striatal neurodegeneration.Interaction between the mu-agonist dermorphin and the delta-agonist [D-Ala2, Glu4]deltorphin in supraspinal antinociception and delta-opioid receptor bindingFingolimod: A Disease-Modifier Drug in a Mouse Model of Amyotrophic Lateral Sclerosis.Aberrant self-grooming as early marker of motor dysfunction in a rat model of Huntington's disease.Adenosine A(2A) receptors modulate BDNF both in normal conditions and in experimental models of Huntington's disease.Influence of CGS 21680, a selective adenosine A(2A) receptor agonist, on NMDA receptor function and expression in the brain of Huntington's disease mice.Striatal 6-OHDA lesion in mice: Investigating early neurochemical changes underlying Parkinson's disease.Remodeling of striatal NMDA receptors by chronic A(2A) receptor blockade in Huntington's disease mice.Adenosine A2A receptor blockade differentially influences excitotoxic mechanisms at pre- and postsynaptic sites in the rat striatum.Permissive role of adenosine A2A receptors on metabotropic glutamate receptor 5 (mGluR5)-mediated effects in the striatum.Unbalance of CB1 receptors expressed in GABAergic and glutamatergic neurons in a transgenic mouse model of Huntington's disease.Nonmotor symptoms in Parkinson's disease: investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model.Neuroprotective effects of thymosin beta4 in experimental models of excitotoxicity.Striatal adenosine-cannabinoid receptor interactions in rats over-expressing adenosine A2A receptors.Pharmacological studies of ‘sapo’ from the frog Phyllomedusa bicolor skin: A drug used by the Peruvian Matses Indians in shamanic hunting practicesEffects of chronic caffeine intake in a mouse model of amyotrophic lateral sclerosisAge-related decline in the functional response of striatal group I mGlu receptorsModulating P1 Adenosine Receptors in Disease Progression of SOD1G93A Mutant Mice
P50
Q28570919-DE7CF045-44E4-4575-BAEA-418707C1EAB6Q28577554-C9BFC256-795A-404F-A764-FC621222E57EQ34081777-B2CDC194-E9BC-4026-8086-B72880CAC251Q34625925-0E48CC0D-E2F0-4B80-B25B-B445FE57882DQ35873168-1005B985-F2D3-4928-B902-F24EC863210FQ39561307-EAE5EBCC-EE8D-4697-88B4-1B3C25126B42Q39635397-4EE6437F-B0C2-411A-8431-0B3E75A00388Q39959489-4E7A1C95-9223-415F-BAEE-4C1FAD05483BQ43170602-0D69AF0F-AD29-4B03-A948-D67D8DAB68F7Q43242127-264F540F-CB79-46C6-B06C-03B92E670A22Q43266904-C4986EB6-A080-41F1-8D7A-769BDC96BC0FQ44937017-25FD555C-180A-4358-83A2-60FE67464AC6Q45018906-8C0C8CFF-250C-4D1D-84C7-422A2CF1AE13Q45305730-2FD8FBFE-EC4A-44F7-8901-10625C1845CFQ46706492-9DA64B9B-270C-407C-B369-1E7B1B90E8D9Q46942207-712A08D1-B7E0-4FC9-9F80-433640A51388Q50917064-6982D69A-A166-42BD-9EE4-031A428157F8Q60060905-2276E0A8-9738-4132-8447-7E9369FDD1F4Q62632838-F9DBD275-1890-4DDD-8A89-CC526D6647FFQ73008898-A1CBB1A0-2DD0-4410-ABD3-55687E254626Q91524154-191A739F-3332-474D-AF58-3B630BB9FF17
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Rosa Luisa Potenza
@ast
Rosa Luisa Potenza
@en
Rosa Luisa Potenza
@es
Rosa Luisa Potenza
@nl
type
label
Rosa Luisa Potenza
@ast
Rosa Luisa Potenza
@en
Rosa Luisa Potenza
@es
Rosa Luisa Potenza
@nl
prefLabel
Rosa Luisa Potenza
@ast
Rosa Luisa Potenza
@en
Rosa Luisa Potenza
@es
Rosa Luisa Potenza
@nl
P106
P1153
35305798500
P21
P31
P496
0000-0003-2342-0705